home

Global News for topic - US

Cerus (CERS) Phase 3 Clinical Trial of INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients Met its Primary Efficacy Endpoint

headline news | recent news | latest news | market news | topics | stock topics

Cerus (CERS) Phase 3 Clinical Trial of INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients Met its Primary Efficacy Endpoint - streetinsider - 12:30 Tue CERS story

Before today

	Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients - marketscreener	12:30 Tue	CERS	marketscreener	story
	Cerus (CERS) Phase 3 Clinical Trial of INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients Met its Primary Efficacy Endpoint - streetinsider	12:30 Tue	CERS	streetinsider	story